The pharmacodynamics and safety of progesterone.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacological mechanisms and safety profiles without systematic search or original data.
PubMed 32739288 · doi:10.1016/j.bpobgyn.2020.06.002
What was done
This narrative review summarizes the pharmacodynamic activity, mechanisms of action, metabolic pathways, and safety profiles of natural progesterone compared to synthetic progestins across reproductive and postmenopausal indications based on published literature.
What was found
The abstract reports no numerical findings or comparative statistics. It describes that natural progesterone and synthetic progestins have variable binding affinities for progesterone, glucocorticoid, androgen, and mineralocorticoid receptors, precluding a shared class effect. Progesterone acts through both nuclear receptors and non-genomic mechanisms, including membrane receptor interactions and calcium influx blockade that relaxes uterine muscle. Route of administration modulates activity; oral administration is altered by gut and hepatic metabolism, whereas vaginal delivery is not. Metabolites such as allopregnanolone positively modulate GABA-A receptors, mediating dose-dependent psychopharmacological and neuroprotective actions.
Why it matters
The review underscores that natural progesterone and synthetic progestins have distinct pharmacodynamic profiles and cannot be assumed to share efficacy or risk profiles across clinical uses.
Limits
As a narrative review, it lacks a systematic search strategy, risk of bias assessments, and quantitative effect estimates. No specific patient sample size or comparative clinical outcome numbers are reported in the abstract.
Cited by
- supports Oral micronized progesterone undergoes extensive first-pass hepatic metabolism where a significant amount is converted into allopregnanolone, which exerts neural calming and sedative effects.